Please login to the form below

Not currently logged in
Email:
Password:

David Meek leaves Novartis to join Endocyte as first chief commercial officer

Joins shortly after major oncology deal with Merck & Co

US biopharma company Endocyte has appointed Novartis' David Meek to the newly created role of chief commercial officer.

Meek leaves Novartis after more than seven years at the Swiss pharma firm where he was most recently the head of northern and central Europe oncology.

Previously, he served as president and CEO of Novartis Pharmaceuticals Canada, where he oversaw the launch of Lucentis and other specialty products, and he also served as the global business franchise head for Novartis' respiratory and dermatology franchise in Basel, Switzerland.

In his new role, Meek will be responsible for the development of Endocyte's commercial team and the company's overall commercial strategy and execution, which includes the deal with Merck & Co made in April, 2012, involving Endocyte's cancer drug vintafolide.

In addition to this drug, Endocyte's products in development include etarfolatide and other targeted small molecule drug conjugates.

"I'm very excited to join the Endocyte team, where I have been compelled by the company's approach to develop innovative therapies accompanied by companion diagnostics," said Meek.

Prior to his time at Novartis, Meek spent 15 years at Johnson & Johnson (J&J), where he held a variety of senior sales and marketing roles across multiple therapeutic areas, including oncology.

30th July 2012

Share



Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Online Physician Communities
Study highlights value of internet for doctors in Eastern Europe
Electronic direct mail is proving popular as online access increases...
England’s clinical commissioning landscape
Who are the real masters in the new NHS?...
How will the new landscape of Hep C treatments affect patients?
The development of new therapeutic agents is set to transform the treatment of hepatitis C over the coming years....